Skip to content
ADVERTISEMENT
Sign In
  • Sections
    • News
    • Advice
    • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Student Success
    • Technology
    • Transitions
    • The Workplace
  • Magazine
    • Current Issue
    • Special Issues
    • Podcast: College Matters from The Chronicle
  • Newsletters
  • Virtual Events
  • Ask Chron
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Professional Development
    • Career Resources
    • Virtual Career Fair
  • More
  • Sections
    • News
    • Advice
    • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Student Success
    • Technology
    • Transitions
    • The Workplace
  • Magazine
    • Current Issue
    • Special Issues
    • Podcast: College Matters from The Chronicle
  • Newsletters
  • Virtual Events
  • Ask Chron
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Professional Development
    • Career Resources
    • Virtual Career Fair
    Upcoming Events:
    A Culture of Cybersecurity
    Opportunities in the Hard Sciences
    Career Preparation
Sign In
Ticker circle logo

The Ticker

Breaking news from all corners of academe.

Reports on Breast-Cancer Drugs Are Often Biased, Research Finds

By Tom Bartlett January 9, 2013

Researchers often exaggerate the benefits and play down the potentially toxic side-effects of breast-cancer drugs in clinical trials, according to a

To continue reading for FREE, please sign in.

Sign In

Or subscribe now to read with unlimited access for as low as $10/month.

Don’t have an account? Sign up now.

A free account provides you access to a limited number of free articles each month, plus newsletters, job postings, salary data, and exclusive store discounts.

Sign Up

Researchers often exaggerate the benefits and play down the potentially toxic side-effects of breast-cancer drugs in clinical trials, according to a new study published in the Annals of Oncology. One way they do this is by emphasizing some secondary benefit of the drug, even if it failed to achieve the primary objective (such as, say, lengthening the life of the patient). High toxicity findings frequently go unmentioned in abstracts and conclusions—perhaps, the authors suggest, “to make the results more attractive.”

The researchers looked at 164 randomized clinical trials from 1995 to 2011 and found evidence of bias in reporting toxicity in 67 percent of those trials. While they note that the pharmaceutical industry is “increasingly influential” in the sponsorship of such trials, they didn’t find any association between industry involvement and bias.

So what do the authors propose be done? Journal editors, regulators, and reviewers should apply “a critical eye to trial reports” to ferret out instances of bias, they say—implying that they have been failing in that responsibility up to now.

We welcome your thoughts and questions about this article. Please email the editors or submit a letter for publication.
Share
  • Twitter
  • LinkedIn
  • Facebook
  • Email
About the Author
Tom Bartlett
Tom Bartlett is a senior writer who covers science and ideas. Follow him on Twitter @tebartl.
ADVERTISEMENT
ADVERTISEMENT

More News

Harvard University
'Deeply Unsettling'
Harvard’s Battle With Trump Escalates as Research Money Is Suddenly Canceled
Photo-based illustration of a hand and a magnifying glass focusing on a scene from Western Carolina Universiy
Equal Opportunity
The Trump Administration Widens Its Scrutiny of Colleges, With Help From the Internet
Santa J. Ono, president of the University of Michigan, watches a basketball game on the campus in November 2022.
'He Is a Chameleon'
At U. of Michigan, Frustrations Grew Over a President Who Couldn’t Be Pinned Down
Photo-based illustration of University of Michigan's president Jeremy Santa Ono emerging from a red shape of Florida
Leadership
A Major College-President Transition Is Defined by an About-Face on DEI

From The Review

Photo illustration of Elon Musk and the Dome of the U.S. Capitol
The Review | Opinion
On Student Aid, It’s Congressional Republicans vs. DOGE
By Robert Gordon, Jordan Matsudaira
Photo-based illustration of a closeup of a blue-toned eye with a small hand either pushing or pulling a red piece of film over the top
The Review | Essay
We Don’t Need More Administrators Inspecting Our Ideas
By Nicolas Langlitz
Solomon-0512 B.jpg
The Review | Essay
The Conscience of a Campus Conservative
By Daniel J. Solomon

Upcoming Events

Ascendium_06-10-25_Plain.png
Views on College and Alternative Pathways
Coursera_06-17-25_Plain.png
AI and Microcredentials
  • Explore Content
    • Latest News
    • Newsletters
    • Letters
    • Free Reports and Guides
    • Professional Development
    • Virtual Events
    • Chronicle Store
    • Chronicle Intelligence
    • Jobs in Higher Education
    • Post a Job
  • Know The Chronicle
    • About Us
    • Vision, Mission, Values
    • DEI at The Chronicle
    • Write for Us
    • Work at The Chronicle
    • Our Reporting Process
    • Advertise With Us
    • Brand Studio
    • Accessibility Statement
  • Account and Access
    • Manage Your Account
    • Manage Newsletters
    • Individual Subscriptions
    • Group and Institutional Access
    • Subscription & Account FAQ
  • Get Support
    • Contact Us
    • Reprints & Permissions
    • User Agreement
    • Terms and Conditions
    • Privacy Policy
    • California Privacy Policy
    • Do Not Sell My Personal Information
1255 23rd Street, N.W. Washington, D.C. 20037
© 2025 The Chronicle of Higher Education
The Chronicle of Higher Education is academe’s most trusted resource for independent journalism, career development, and forward-looking intelligence. Our readers lead, teach, learn, and innovate with insights from The Chronicle.
Follow Us
  • twitter
  • instagram
  • youtube
  • facebook
  • linkedin